Abbott Laboratories $ABT Shares Sold by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 7.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 897,482 shares of the healthcare product maker’s stock after selling 71,572 shares during the period. Bahl & Gaynor Inc.’s holdings in Abbott Laboratories were worth $120,209,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ABT. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $31,000. Anfield Capital Management LLC grew its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the second quarter worth $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the third quarter valued at $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Argus decreased their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Sanford C. Bernstein reduced their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Raymond James Financial decreased their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Piper Sandler cut their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Finally, Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $116.17 on Monday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The firm’s 50-day moving average price is $117.34 and its two-hundred day moving average price is $125.23. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The stock has a market capitalization of $201.87 billion, a P/E ratio of 31.23, a P/E/G ratio of 1.85 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.